Frontiers in Oncology (Jun 2023)

LC–MS-based serum metabolomics analysis for the screening and monitoring of colorectal cancer

  • Yanan Yi,
  • Jianjian Wang,
  • Chengtong Liang,
  • Chuanli Ren,
  • Xu Lian,
  • Chongxu Han,
  • Wei Sun

DOI
https://doi.org/10.3389/fonc.2023.1173424
Journal volume & issue
Vol. 13

Abstract

Read online

BackgroundColorectal Cancer (CRC) is a prevalent digestive system tumour with significant mortality and recurrence rates. Serum metabolomics, with its high sensitivity and high throughput, has shown potential as a tool to discover biomarkers for clinical screening and monitoring of the CRC patients.MethodsSerum metabolites of 61 sex and age-matched healthy controls and 62 CRC patients (before and after surgical intervention) were analyzed using a ultra-performance liquid chromatography-high resolution mass spectrometer (UPLC-MS). Statistical methods and pathway enrichment analysis were used to identify potential biomarkers and altered metabolic pathways.ResultsOur analysis revealed a clear distinction in the serum metabolic profile between CRC patients and healthy controls (HCs). Pathway analysis indicated a significant association with arginine biosynthesis, pyrimidine metabolism, pantothenate, and CoA biosynthesis. Univariate and multivariate statistical analysis showed that 9 metabolites had significant diagnostic value for CRC, among them, Guanosine with Area Under the Curve (AUC) values of 0.951 for the training group and0.998 for the validation group. Furthermore, analysis of four specific metabolites (N-Phenylacetylasparticacid, Tyrosyl-Gamma-glutamate, Tyr-Ser and Sphingosine) in serum samples of CRC patients before and after surgery indicated a return to healthy levels after an intervention.ConclusionOur results suggest that serum metabolomics may be a valuable tool for the screening and monitoring of CRC patients.

Keywords